T1	Outcomes 0 40	Safety, tolerability, and immunogenicity
T2	Outcomes 523 560	compared immunity and safety profiles
T3	Outcomes 618 626	placebo.
T4	Outcomes 627 641	Immunogenicity
T5	Outcomes 656 807	using VZV interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) assay and VZV glycoprotein enzyme-linked immunosorbent antibody (gpELISA) assay.
T6	Outcomes 808 833	Adverse experiences (AEs)
T7	Outcomes 891 898	RESULTS
T8	Outcomes 902 925	serious vaccine-related
T9	Outcomes 930 939	occurred.
T10	Outcomes 940 1046	VZV IFN-γ ELISPOT geometric mean count (GMC) of spot-forming cells per 10(6) peripheral blood mononuclear
T11	Outcomes 1196 1206	postdose 2
T12	Outcomes 1238 1250	respectively
T13	Outcomes 1310 1335	The peak ELISPOT response
T14	Outcomes 1370 1375	dose.
T15	Outcomes 1376 1409	The gpELISA geometric mean titers
T16	Outcomes 1488 1498	each dose.
T17	Outcomes 1499 1549	Correlation between the IFN-γ ELISPOT and gpELISA
T18	Outcomes 1586 1626	generally well-tolerated and immunogenic
T19	Outcomes 1674 1687	was generally
T20	Outcomes 1712 1724	VZV-specific
